






The limb-to-waist ratio: resolving the divergence between mortality and cardiovascular risk

Shenghao Zuo^{1,†} , Tongshuai Guo^{1,†}, Hui Ren^{2,†}, Hang Cao³, Yanjie Yang¹, Ruiyu Wang¹, Chenyang Liu¹, Yan Zhuo¹, Tian Xia¹, Xiao Yuan¹, Mingke Chang¹, Guilin Hu¹, Yue Sun¹, Xi Zhang¹, Mingfei Du¹, Hao Jia¹, Ziyue Man¹, Teng Zhang¹, Jianjun Mu^{1,†} , Mei Zuo^{3,†} 

Keywords:

Arm circumference, thigh circumference, waist circumference, body composition, mortality, cardiovascular risk factors

Citation: Zuo S, Guo T, Ren H, Cao H, Yang Y, Wang R, Liu C, Zhuo Y, Xia T, Yuan X, Chang M, Hu G, Sun Y, Zhang X, Du M, Jia H, Man Z, Zhang T, Mu J, Zuo M. The limb-to-waist ratio: resolving the divergence between mortality and cardiovascular risk. *Vessel Plus*. 2026;10:19. <https://dx.doi.org/10.20517/2574-1209.2025.147>

Received: 8 Dec 2025

First Decision: 26 Jan 2026

Revised: 7 Feb 2026

Accepted: 1 Apr 2026

Published: 15 May 2026

Academic Editor:


Aijun Sun

Copy Editor:

Fangling Lan

Production Editor:

Fangling Lan



Abstract

Aim: We aimed to resolve the paradoxical associations of limb circumference—inverse with mortality but positive with cardiovascular risk factors (CVRFs)—by systematically comparing the predictive value of the ratio of combined arm and thigh circumference (ATC) to waist circumference (WC) against that of the sum of ATC for mortality and key CVRFs.

Methods: Our analysis utilized data from 17,276 U.S. participants in the 1999-2006 NHANES (National Health and Nutrition Examination Survey). We utilized Cox proportional hazards, generalized linear, and restricted cubic spline models, with comprehensive adjustment for confounders including adiposity. The outcomes assessed were all-cause and cardiovascular mortality, hypertension, diabetes, and resting tachycardia.

¹Department of Cardiology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.

²Department of Cardiology, Ankang Central Hospital, Ankang 725000, Shaanxi, China.

³Department of Cardiology, Yan'an University Xianyang Hospital, Xianyang 712000, Shaanxi, China.

[†]Authors contributed equally.

[†]Authors contributed equally to this work and are co-corresponding authors.

Correspondence to: Prof. Mei Zuo, Department of Cardiology, Yan'an University Xianyang Hospital, No. 38, Middle Section of Wenlin Road, Weicheng District, Xianyang 712000, Shaanxi, China. E-mail: zuoyimei123@163.com; Dr. Jian-jun Mu, Department of Cardiology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, 277 Yanta West Road, Xi'an 710061, Shaanxi, China. E-mail: mujun@163.com

Results: During median 18.04-year follow-up (3,927 deaths, 1,047 cardiovascular deaths), the highest versus lowest ATC/WC quartile showed consistently protective associations: all-cause mortality (hazard ratio (HR) = 0.47, 95% confidence interval (95%CI): 0.38-0.57), cardiovascular mortality (HR = 0.32, 0.21-0.49), hypertension (OR = 0.49, 0.41-0.59), diabetes (odds ratio (OR) = 0.26, 0.18-0.37), and resting tachycardia (OR = 0.28, 0.19-0.39; all $P < 0.001$). Conversely, ATC exhibited adiposity-dependent paradoxical associations: protective for mortality but harmful for CVRFs when unadjusted for adiposity. After adiposity adjustment, ATC's harmful CVRFs associations were attenuated or reversed, while mortality benefits persisted. ATC/WC demonstrated superior linearity in dose-response relationships compared to ATC.

Conclusion: The ATC/WC ratio consistently demonstrates protective associations with both mortality and CVRFs. The waist standardization approach clarifies the relationship between limb measurements, cardiovascular health, and mortality by adjusting for central adiposity-related confounding that limits the utility of absolute rather than relative peripheral limb measurements.

INTRODUCTION

Cardiovascular disease (CVD) stands as the preeminent contributor to the global burden of mortality^[1]. Early intervention on modifiable risk factors prior to the onset of endpoint events is crucial for reducing the disease burden^[2,3]. Limb circumferences reflect the composition of peripheral limbs, primarily comprising muscle mass, subcutaneous fat, bone structure, and excessive or ectopic adipose tissue^[4-6]. Numerous studies have indicated that larger limb circumferences are consistently linked to a reduction in risk for both all-cause and cardiovascular mortality, suggesting their potential as markers of overall health and nutritional status^[7].

However, the associations between limb circumference and specific cardiovascular risk factors (CVRFs), including hypertension and diabetes, are complex and inconsistent. Some studies associate larger limb circumferences with a higher risk of these conditions^[8-11], while others have reported no association or even a protective effect against these risks^[12-14]. This apparent paradox, where benefits for mortality contrast with mixed effects on risk factors, constitutes a significant scientific question. We hypothesize that this discrepancy stems from the fact that limb circumference is a composite measure, simultaneously capturing both metabolically beneficial tissues (e.g., lean mass, bone, subcutaneous fat) and potentially detrimental adipose tissue^[15-17]. This heterogeneity in composition makes the health effects of a simple circumference measurement difficult to interpret clearly. Waist circumference (WC) is a reliable indicator of central obesity and visceral fat accumulation, which is a key driver of cardiometabolic risk^[18]. Therefore, we propose that standardizing limb circumference for WC (e.g., by calculating a ratio) may effectively adjust for overall adiposity. Under this premise, a protective association between this ratio and health outcomes could be interpreted as primarily reflecting the relative abundance of protective tissues (e.g., muscle, subcutaneous fat) in the limbs relative to the level of overall adiposity, offering a mechanistic explanation for the aforementioned contradiction. Preliminary evidence from two studies supports that limb circumference-to-waist circumference ratios are associated with reduced mortality and increased muscle mass and strength^[19,20]; however, their association with comprehensive cardiovascular health outcomes, including both mortality and multiple CVRFs, has not been systematically evaluated.

To address this gap, this study utilizes National Health and Nutrition Examination Survey (NHANES) data to evaluate the ratios of upper-arm and thigh circumference to WC. Their associations with prospective mortality outcomes (all-cause, cardiovascular) and cross-sectional conditions outcomes (hypertension, diabetes, resting tachycardia) will be evaluated using longitudinal and cross-sectional analyses, respectively.

METHODS

Study design and participants

NHANES utilizes a multi-stage probability-based sampling methodology to yield a nationally representative sample of the non-institutionalized U.S. civilian population. Since 1999, NHANES has operated in two-year cycles, collecting comprehensive data through interviews, physical examinations, and laboratory analyses. Detailed study design information is publicly available^[21]. A total of 41,474 subjects participated in NHANES between 1999 and 2006. After excluding 18,850 participants aged less than 18, 4,498 with missing hypertension, diabetes, and heart rate data, 835 missing AC, TC, and WC data, and 15 lacking mortality data, we ended up with a final of 17,276 individuals [Supplementary Figure 1]. The use of de-identified, publicly available NHANES data waived the requirement for Institutional Review Board review.

Limb and waist circumference measurements

Trained healthcare technicians measured right arm circumference (AC), right thigh circumference (TC), and WC following standardized protocols. The left limb was measured if the right was unavailable. For AC, participants stood with arms naturally hanging, elbows bent at 90°, and palms facing upward. AC was measured at the midpoint between the acromion's posterior edge and the olecranon process (tip of the elbow), with the tape positioned perpendicular to the long axis of the upper arm. For TC, participants first sat with knees bent at 90°, and a mark was made at the midpoint between the inguinal crease and the proximal edge of the patella. Participants then stood, shifted their weight to the left leg, slightly flexed the right leg forward, and TC was measured perpendicular to the long axis at the marked point. WC was measured while standing by marking a horizontal line just above the right iliac crest and measuring WC along this line. All measurements were recorded to the nearest millimeter. The sum of arm and thigh circumference (ATC) was defined as the sum of unilateral AC and TC, and ATC/WC was calculated as the ratio of ATC to WC.

Mortality and cardiovascular risk factors

Using a unique identifier, each participant was linked to the National Death Index, with follow-up for mortality available through December 31, 2019^[22]. Mortality endpoints included death from any cause (all-cause mortality) and death from cardiovascular diseases, as determined by the following ICD-10 codes: I00-I09, I11, I13, and I20-I51.

Blood pressure (BP), blood samples, resting heart rate measurements, and related questionnaire data were collected at baseline. BP was measured at the Mobile Examination Center (MEC) using a mercury sphygmomanometer. After a 5-min seated rest, three consecutive readings of systolic and diastolic BP were obtained after determining the maximum inflation level; a fourth reading was taken if any measurement was unsuccessful. The final BP value was the average of the valid readings. Hypertension was defined as systolic BP exceeding 140 mmHg, diastolic BP exceeding 90 mmHg, and/or a self-reported physician diagnosis. Blood samples were rapidly centrifuged after collection at the MEC and sent to Johns Hopkins Hospital (Baltimore, MD), where fasting glucose and hemoglobin A1c (HbA1c) levels were determined using a Hitachi automated analyzer. Diabetes was defined as fasting blood glucose over 7 mmol/L, HbA1c above 6.5%, and/or self-reported diagnosis, use of hypoglycemic medications or insulin therapy. Sample processing and assays adhered to NHANES standardized protocols^[23]. Resting heart rate was determined by counting the beats in 30 s and multiplying by two. According to the ESC Tachycardia Management Guidelines, resting tachycardia was defined as a heart rate greater than 100 beats per minute^[24].

Covariates

Covariates were selected based on established clinical and epidemiological relevance, and were categorized into three domains. (1) Sociodemographic factors: age (categorized as 18-30, 30-42, 42-54, 54-66, > 66 years),

sex, race/ethnicity, education level, marital status, and family income-to-poverty ratio (< 1 or ≥ 1); (2) Lifestyle factors: smoking and alcohol consumption status; (3) Physical health indicators: body mass index (BMI), serum creatinine, urine albumin-to-creatinine ratio (uACR), and history of underlying diseases. Participants were considered to have a history of underlying diseases if they reported a prior diagnosis of bronchitis, asthma, coronary heart disease, congestive heart failure, stroke, or malignant tumors.

Statistical analyses

Analyses accounted for the NHANES complex survey design (weights, clustering, stratification) and were performed in R 4.5.1. Missing covariate data were imputed via random forest. Continuous variables are summarized as weighted mean (standard deviation), and categorical variables as weighted frequency (percentage). Group comparisons utilized the weighted Kruskal-Wallis test for continuous variables and the weighted chi-square test for categorical variables. A two-sided P -value < 0.05 was deemed statistically significant.

To evaluate survival patterns, Kaplan-Meier curves were generated for ATC/WC and ATC across age subgroups, stratified by all-cause and cardiovascular mortality. To assess mortality risk, Cox proportional hazards models were fitted. The associations of ATC/WC and ATC with hypertension, diabetes, and resting tachycardia were examined using generalized linear models. We employed a multi-model adjustment strategy. Model 1 was unadjusted (crude); Model 2 adjusted for basic sociodemographic and lifestyle factors, including smoking and alcohol consumption; Model 3 further adjusted for clinical measures and comorbidities, including serum creatinine, uACR, dyslipidemia, and a history of underlying diseases—and, for mortality outcomes, additionally for baseline hypertension, diabetes, and tachycardia; and Model 4 additionally adjusted for BMI (fully adjusted). For ATC, a sensitivity analysis (Model 5) replaced adjustment for BMI with adjustment for WC. In Model 4, potential nonlinearity was explored using restricted cubic splines with three knots.

We conducted an extensive set of sensitivity analyses. First, we performed subgroup analyses based on age, sex, hypertension, diabetes, smoking status, and history of underlying diseases to assess how ATC/WC and ATC were related to both all-cause and cardiovascular mortality, as well as to CVRFs. Second, we substituted measured BP values for the hypertension diagnosis variable, fasting glucose measurements for the diabetes diagnosis variable, and resting heart rate measurements for the resting tachycardia variable, utilizing linear regression to assess the correlations between ATC/WC, ATC, and CVRFs—to mitigate potential misclassification and validate our primary findings. Finally, to deconstruct the composite metrics, we evaluated the individual components: we examined the associations of unilateral AC and TC separately with mortality and CVRF, and we also constructed and tested arm-to-waist (AC/WC) and thigh-to-waist (TC/WC) ratios.

RESULTS

Baseline characteristics

This study comprised a final cohort of 17,276 individuals. According to weighted quartiles of ATC/WC (cut points: 0.839, 0.902, 0.965), participants were categorized into four groups: Q1 ($n = 5,213$), Q2 ($n = 4,112$), Q3 ($n = 3,776$), and Q4 ($n = 4,175$). Over a median follow-up of 18.04 years (totaling 358,477 person-years), 3,927 deaths occurred, including 1,047 cardiovascular deaths. The cohort had a mean age of 46.08 (± 20.12) years and was 52% female. As detailed in [Table 1](#), when contrasting baseline characteristics, individuals in Q4 were generally younger, had higher educational attainment, and lower smoking prevalence than those in Q1. They also presented with more favorable anthropometric and clinical profiles, including lower values for WC, weight, BMI, serum creatinine, total cholesterol, BP, and resting heart rate. Moreover, the prevalence of multiple comorbidities—including proteinuria, hypertension, diabetes, dyslipidemia, chronic bronchitis, coronary heart disease, heart failure, stroke, and cancer—was lower in Q4 relative to Q1.

Table 1. Distribution of baseline characteristics across quartiles of ATC/WC

Characteristics	Total	Q1 ^a	Q2	Q3	Q4	P value
Number	17,276	5,213	4,112	3,776	4,175	
Female (%)	9,008 (52.0)	2,333 (42.4)	2,142 (47.8)	2,126 (54.8)	2,407 (63.1)	< 0.0001
Age, years	46.08 (20.12)	60.24 (18.40)	48.02 (17.86)	39.65 (16.52)	32.31 (14.50)	< 0.0001
Age group (%)						< 0.0001
≥ 18 and ≤ 30	5,007 (23.5)	548 (6.7)	830 (15.2)	1,318 (27.7)	2,311 (44.4)	
> 30 and ≤ 42	3,185 (23.8)	442 (11.1)	833 (24.3)	976 (31.2)	934 (28.8)	
> 42 and ≤ 54	3,023 (24.4)	728 (23.3)	964 (30.8)	774 (25.3)	557 (18.2)	
> 54 and ≤ 66	2,630 (14.7)	1,207 (24.8)	766 (17.7)	421 (10.3)	236 (6.2)	
> 66	3,431 (13.5)	2,288 (34.1)	719 (12.0)	287 (5.5)	137 (2.5)	
Ethnicity (%)						< 0.0001
Mexican American	3,997 (7.5)	1,331 (7.3)	1,095 (9.4)	917 (8.0)	654 (5.3)	
Non-Hispanic Black	3,544 (10.6)	543 (5.4)	703 (8.4)	757 (9.9)	1,541 (18.6)	
Non-Hispanic White	8,398 (72.3)	2,990 (79.0)	1,982 (72.5)	1,777 (71.5)	1,649 (66.4)	
Others	1,337 (9.6)	349 (8.3)	332 (9.7)	325 (10.6)	331 (9.8)	
Married (%)	9,916 (63.5)	3,350 (67.3)	2,654 (68.0)	2,165 (65.1)	1,747 (53.5)	< 0.0001
High School or above (%)	12,060 (80.9)	3,185 (74.7)	2,801 (79.7)	2,788 (84.2)	3,286 (85.1)	< 0.0001
Not poor (%)	13,900 (87.2)	4,244 (87.1)	3,297 (87.3)	3,049 (87.7)	3,310 (86.6)	0.703
Currently smoking (%)	3,381 (23.8)	914 (22.5)	936 (26.4)	786 (23.7)	745 (22.6)	0.014
Currently drinking (%)	1,1782 (72.8)	3,432 (69.5)	2,826 (73.8)	2,580 (73.0)	2,944 (74.8)	0.0017
WC, cm	96.44 (15.49)	106.29(13.91)	99.21 (13.17)	92.88 (12.86)	84.64 (12.32)	< 0.0001
BMI, kg/m ²	28.08 (6.17)	29.44 (6.00)	28.76 (5.96)	27.57 (6.05)	26.18 (6.18)	< 0.0001
HDL-C, mg/dL ^b	53.28 (15.83)	50.97 (15.83)	52.12 (16.22)	53.28 (15.44)	56.37 (15.44)	< 0.0001
Total cholesterol, mg/dL ^b	198.84 (44.02)	207.34 (45.17)	207.34 (44.79)	196.14 (42.47)	182.63 (38.22)	< 0.0001
Creatinine, mg/dL ^b	0.88 (0.45)	0.94 (0.56)	0.86 (0.46)	0.84 (0.37)	0.86 (0.32)	< 0.0001
uACR, mg/g	48.66 (408.06)	98.82 (633.05)	36.68 (335.95)	23.81 (222.81)	20.29 (167.44)	< 0.0001
Comorbidity Model (%)	4,258 (25.0)	1,829 (37.4)	942 (23.2)	707 (18.8)	780 (20.7)	< 0.0001
Coronary artery disease (%)	666 (3.4)	447 (8.6)	139 (3.3)	52 (1.0)	28 (0.6)	< 0.0001
Congestive heart failure (%)	470 (2.1)	318 (5.6)	84 (1.5)	48 (1.0)	20 (0.3)	< 0.0001
Stroke (%)	512 (2.4)	310 (5.2)	118 (2.4)	54 (1.5)	30 (0.7)	< 0.0001
Chronic bronchitis (%)	427 (2.8)	180 (4.2)	116 (3.3)	81 (2.3)	50 (1.5)	< 0.0001
Asthma (%)	2,046 (12.9)	560 (12.8)	439 (11.5)	443 (11.9)	604 (15.5)	0.0003
Cancer (%)	1,327 (8.1)	726 (15.6)	304 (7.3)	166 (5.0)	131 (4.5)	< 0.0001
SBP, mmHg	124.36 (20.34)	132.47 (22.45)	125.64 (20.26)	120.23 (17.57)	116.73 (15.56)	< 0.0001
DBP, mmHg	69.33 (14.02)	68.69 (16.04)	70.90 (13.79)	69.82 (13.21)	68.14 (11.92)	< 0.0001
Heart rate, beats/ min	72.78 (12.66)	73.43 (13.70)	73.19 (12.76)	72.77 (12.01)	71.59 (11.64)	< 0.0001
Hypertension (%)	6,454 (34.7)	3,063 (59.2)	1,650 (37.1)	1,018 (25.6)	723 (17.1)	< 0.0001
Diabetes (%)	2,187 (10.3)	1,365 (24.5)	497 (9.8)	197 (4.1)	128 (2.7)	< 0.0001
Hyperlipidemia (%)	11,885 (66.9)	4,142 (81.4)	3,096 (74.7)	2,414 (62.5)	2,233 (49.2)	< 0.0001

^aQ1: ATC/WC < 0.839; Q2: 0.839 ≤ ATC/WC < 0.902; Q3: 0.902 ≤ ATC/WC < 0.965; Q4: ATC/WC ≥ 0.965; ^bSI unit conversions: Cholesterol: 1 mg/dL = 0.0259 mmol/L; Creatinine: 1 mg/dL = 88.4 μmol/L. Group comparisons were performed using the weighted Kruskal-Wallis test for continuous variables and the weighted chi-square test for categorical variables.

Table 2. Cox proportional hazards model for ATC/WC, ATC and all-cause and cardiovascular mortality

Characteristics	Model 1 ^a HR (95%CI)	Model 2 ^b HR (95%CI)	Model 3 ^c HR (95%CI)	Model 4 ^d HR (95%CI)	Model 5 ^e HR (95%CI)
All-cause death (3,927/17,276)					
ATC/WC					
Q1	Ref	Ref	Ref	Ref	-
Q2	0.33 (0.30-0.37)	0.63 (0.56-0.72)	0.72 (0.63-0.82)	0.70 (0.61-0.80)	-
Q3	0.18 (0.16-0.21)	0.58 (0.50-0.67)	0.68 (0.58-0.79)	0.65 (0.55-0.77)	-
Q4	0.09 (0.08-0.11)	0.42 (0.35-0.52)	0.49 (0.40-0.60)	0.47 (0.38-0.57)	-
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	-
ATC					
Q1	Ref	Ref	Ref	Ref	Ref
Q2	0.61 (0.56-0.67)	0.66 (0.59-0.73)	0.65 (0.58-0.72)	0.58 (0.52-0.66)	0.56 (0.49-0.63)
Q3	0.52 (0.46-0.59)	0.65 (0.59-0.73)	0.60 (0.54-0.68)	0.50 (0.43-0.58)	0.46 (0.41-0.53)
Q4	0.47 (0.41-0.54)	0.78 (0.68-0.90)	0.68 (0.60-0.78)	0.47 (0.38-0.57)	0.42 (0.35-0.51)
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*
Cardiovascular death (1,047/17,276)					
ATC/WC					
Q1	Ref	Ref	Ref	Ref	-
Q2	0.32 (0.26-0.40)	0.63 (0.51-0.79)	0.73 (0.58-0.93)	0.73 (0.57-0.93)	-
Q3	0.13 (0.09-0.18)	0.44 (0.31-0.63)	0.55 (0.38-0.79)	0.54 (0.37-0.79)	-
Q4	0.05 (0.03-0.07)	0.25 (0.17-0.40)	0.33 (0.22-0.49)	0.32 (0.21-0.49)	-
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	-
ATC					
Q1	Ref	Ref	Ref	Ref	Ref
Q2	0.61 (0.50-0.75)	0.64 (0.53-0.78)	0.62 (0.51-0.75)	0.54 (0.45-0.66)	0.51 (0.42-0.62)
Q3	0.53 (0.43-0.65)	0.66 (0.52-0.83)	0.57 (0.45-0.72)	0.45 (0.35-0.59)	0.41 (0.32-0.53)
Q4	0.57 (0.43-0.74)	0.98 (0.76-1.25)	0.80 (0.62-1.04)	0.51 (0.34-0.76)	0.43 (0.31-0.61)
p for trend	< 0.001*	0.474	0.037*	< 0.001*	< 0.001*

^aModel 1: unadjusted; ^bModel 2: adjusted for age, sex, race, marital status, education, family income-poverty ratio, smoking, and drinking; ^cModel 3: Model 2 plus further adjusted for creatinine, uACR, hyperlipidemia, hypertension, diabetes, high resting heart rate, history of underlying diseases; ^dModel 4: Model 3 plus further adjusted for BMI; ^eModel 5: Sensitivity model, model 3 plus further adjusted for WC. **P* < 0.05. Assessed using multivariable weighted Cox regression.

Associations of ATC/WC and ATC with mortality

Kaplan-Meier analyses stratified by age indicated protective associations for both ATC/WC and ATC with mortality, though the associations emerged in different age groups [Supplementary Figures 2 and 3]. This study evaluated the association between the ATC/WC ratio and mortality using multivariable-adjusted Cox proportional hazards models, confirming significant and independent inverse associations (see Table 2 for details). In Model 3, which did not adjust for BMI or waist circumference, participants in the highest quartile (Q4) of ATC/WC, compared to those in the lowest quartile (Q1), showed a significantly lower risk of all-cause mortality, with a hazard ratio (HR) of 0.49 (95% confidence interval [CI]: 0.40-0.60). The reduction in cardiovascular mortality risk was more pronounced, with an HR of 0.33 (95% confidence interval (95%CI): 0.22-0.49). Notably, the strength of these protective associations remained virtually unchanged after further adjustment for BMI in Model 4 (all-cause mortality: HR = 0.47, 95%CI: 0.38-0.57; cardiovascular mortality: HR = 0.32, 95%CI: 0.21-0.49), demonstrating that ATC/WC effectively accounts for adiposity.




Figure 1. ATC/WC and all-cause mortality and cardiovascular mortality. The association was analyzed using a restricted cubic spline model, adjusted for age, sex, race, marital status, education, family income-poverty ratio, BMI, smoking, drinking, creatinine, uACR, hyperlipidemia, and history of underlying diseases. (A) Association between ATC/WC and all-cause mortality. (B) Association between ATC/WC and cardiovascular mortality.

In contrast, the associations for ATC were confounded by overall adiposity. In model 3 (without BMI/WC adjustment), a higher ATC (Q4 vs. Q1) was associated with only a modest reduction in all-cause mortality risk (HR = 0.68, 95%CI: 0.60-0.78), while its association with cardiovascular mortality did not reach statistical significance (HR = 0.80, 95%CI: 0.62-1.04). However, after adjusting for BMI in model 4, the associations strengthened substantially, becoming significantly inverse for both all-cause (HR = 0.47, 95%CI: 0.38-0.57) and cardiovascular mortality (HR = 0.51, 95%CI: 0.34-0.76). This reversal underscores that the true protective effect of limb circumference is masked by its correlation with general obesity and requires control for adiposity.

RCS analyses visually supported these associations. For the ATC/WC, the relationship with mortality was significantly linear. The *P*-value for non-linearity was 0.255 for all-cause [Figure 1A] and 0.171 for cardiovascular mortality [Figure 1B]. The mortality risk decreased steadily as ATC/WC increased, with a threshold of notable protection above a value of 0.835. In contrast, the association between ATC and mortality was significantly non-linear (*P* for non-linearity < 0.001), as detailed in Supplementary Figure 4.

Associations of ATC/WC and ATC with cardiovascular risk factors

The prevalence of hypertension [Figure 2A], diabetes [Figure 2B], and resting tachycardia [Figure 2C] decreased significantly with increasing quartiles of ATC/WC (all *P* < 0.001). In contrast, while ATC quartiles were significantly associated with the prevalence of hypertension [Figure 2D] and diabetes [Figure 2E] (*P* < 0.001), the relationships appeared nonlinear. No significant association was observed between ATC and the prevalence of resting tachycardia (Figure 2F, *P* = 0.478).

In logistic regression of model 3, participants in Q4 of ATC/WC had substantially lower odds of hypertension (odds ratio (OR) = 0.36, 95%CI: 0.30-0.42), diabetes (OR = 0.19, 95%CI: 0.13-0.26), and resting tachycardia (OR = 0.25, 95%CI: 0.18-0.37) compared to Q1. Critically, these robust protective associations persisted after further adjustment for BMI in model 4, with ORs of 0.49 (95%CI: 0.41-0.59) for hypertension,




Figure 2. Prevalence of hypertension, diabetes, and resting tachycardia based on ATC/WC and ATC quartile grouping. Group comparisons were performed using the weighted chi-square test. (A) Hypertension weighted prevalence and case number by ATC/WC quartiles. (B) Diabetes weighted prevalence and case number by ATC/WC quartiles. (C) Resting tachycardia weighted prevalence and case number by ATC/WC quartiles. (D) Hypertension weighted prevalence and case number by ATC quartiles. (E) Diabetes weighted prevalence and case number by ATC quartiles. (F) Resting tachycardia weighted prevalence and case number by ATC quartiles.

0.26 (95%CI: 0.18-0.37) for diabetes, and 0.28 (95%CI: 0.19-0.39) for resting tachycardia [Table 3], underscoring the ability of ATC/WC to effectively account for adiposity.

In contrast, the associations for ATC alone were confounded by overall adiposity. Before adjustment for BMI or WC (model 3), a larger ATC (Q4 vs. Q1) was paradoxically associated with higher odds of hypertension (OR = 2.70, 95%CI: 2.37-3.07) and diabetes (OR = 2.95, 95%CI: 2.40-3.62), and showed a non-significant trend for resting tachycardia (OR = 1.23, 95%CI: 0.84-1.78). However, after adjusting for BMI (model 4), these adverse associations were not only eliminated but reversed, revealing significant protective effects for hypertension (OR = 0.74, 95%CI: 0.59-0.93) and diabetes (OR = 0.34, 95%CI: 0.24-0.48), and a non-significant protective trend for tachycardia (OR = 0.65, 95%CI: 0.37-1.14). Sensitivity analyses adjusting for WC yielded consistent results. This pattern unequivocally demonstrates that the true protective association of limb circumference is masked by its correlation with overall adiposity.

For ATC/WC, a linear inverse association was observed for hypertension (p non-linear = 0.89), as shown in Figure 3A, while its relationships with diabetes (p non-linear = 0.004) and resting tachycardia (p non-linear = 0.026) exhibited significant non-linear components, as shown in Figure 3B and C. Protective effects appear when ATC/WC exceeds 0.89. ATC showed a linear correlation with hypertension and a nonlinear correlation with diabetes and resting tachycardia [Supplementary Figure 5].

Additional and sensitivity analysis

The robustness of the primary findings and potential underlying mechanisms were evaluated through a set of sensitivity analyses.

First, we confirmed the fundamental source of confounding for ATC by demonstrating its significant, linear positive correlations with both BMI and WC [Supplementary Figure 6]. Consistently, higher ATC was linked to greater odds of both general and abdominal obesity [Supplementary Table 1], directly explaining its

Table 3. Generalized liner regression for ATC/WC, ATC and cardiovascular risk factors

Characteristics	Model 1 ^a OR (95%CI)	Model 2 ^b OR (95%CI)	Model 3 ^c OR (95%CI)	Model 4 ^d OR (95%CI)	Model 5 ^e OR (95%CI)
Hypertension (6,454/17,276)					
ATC/WC					
Q1	Ref	Ref	Ref	Ref	-
Q2	0.41(0.36-0.46)	0.60(0.51-0.71)	0.63(0.54-0.75)	0.73(0.62-0.86)	-
Q3	0.24(0.21-0.27)	0.45(0.40-0.52)	0.50(0.43-0.57)	0.63(0.55-0.73)	-
Q4	0.14(0.12-0.17)	0.32(0.27-0.38)	0.36(0.30-0.42)	0.49(0.41-0.59)	-
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	-
ATC					
Q1	Ref	Ref	Ref	Ref	Ref
Q2	1.00 (0.97-1.03)	1.16 (1.01-1.33)	1.16 (1.01-1.33)	0.81 (0.70-0.94)	0.83 (0.71-0.96)
Q3	1.04 (1.02-1.06)	1.65 (1.46-1.86)	1.60 (1.40-1.82)	0.81 (0.67-0.98)	0.86 (0.73-1.02)
Q4	1.13 (1.10-1.16)	2.89 (2.53-3.30)	2.70 (2.37-3.07)	0.74 (0.59-0.93)	0.87 (0.71-1.05)
p for trend	< 0.001*	< 0.001*	< 0.001*	0.027*	0.231
Diabetes (2,187/17,276)					
ATC/WC					
Q1	Ref	Ref	Ref	Ref	-
Q2	0.33 (0.29-0.39)	0.41 (0.35-0.49)	0.43 (0.37-0.52)	0.51 (0.43-0.61)	-
Q3	0.13 (0.11-0.16)	0.20 (0.16-0.25)	0.22 (0.18-0.28)	0.29 (0.23-0.36)	-
Q4	0.09 (0.07-0.11)	0.16 (0.11-0.23)	0.19 (0.13-0.26)	0.26 (0.18-0.37)	-
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	-
ATC					
Q1	Ref	Ref	Ref	Ref	Ref
Q2	1.07 (0.89-1.28)	1.21 (1.02-1.45)	1.25 (1.04-1.51)	0.70 (0.56-0.88)	0.67 (0.54-0.84)
Q3	1.39 (1.16-1.66)	1.81 (1.50-2.18)	1.85 (1.53-2.23)	0.63 (0.50-0.80)	0.61 (0.49-0.77)
Q4	1.84 (1.51-2.24)	2.96 (2.43-3.62)	2.95 (2.40-3.62)	0.34 (0.24-0.48)	0.35 (0.27-0.47)
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*
Resting tachycardia rates (536/17,276)					
ATC/WC					
Q1	Ref	Ref	Ref	Ref	-
Q2	0.54 (0.39-0.75)	0.44 (0.32-0.61)	0.47 (0.34-0.64)	0.48 (0.35-0.67)	-
Q3	0.50 (0.36-0.69)	0.36 (0.26-0.50)	0.40 (0.28-0.56)	0.42 (0.30-0.60)	-
Q4	0.37 (0.27-0.51)	0.22 (0.15-0.32)	0.25 (0.18-0.37)	0.28 (0.19-0.39)	-
p for trend	< 0.001*	< 0.001*	< 0.001*	< 0.001*	-
ATC					
Q1	Ref	Ref	Ref	Ref	Ref
Q2	0.84 (0.57-1.25)	0.95 (0.63-1.43)	0.94 (0.62-1.43)	0.78 (0.51-1.19)	0.67 (0.44-1.01)
Q3	0.64 (0.48-0.86)	0.78 (0.57-1.05)	0.75 (0.55-1.03)	0.52 (0.37-0.75)	0.39 (0.29-0.54)
Q4	1.23 (0.84-1.78)	1.43 (0.97-2.11)	1.34 (0.91-1.96)	0.65 (0.37-1.14)	0.38 (0.23-0.62)
p for trend	0.478	0.133	0.234	0.029*	< 0.001*

^aModel 1: unadjusted; ^bModel 2: adjusted for age, sex, race, marital status, education, family income-poverty ratio, smoking, and drinking; ^cModel 3: Model 2 plus further adjusted for creatinine, uACR, hyperlipidemia, hypertension, diabetes, high resting heart rate, history of underlying diseases; ^dModel 4: Model 3 plus further adjusted for BMI; ^eModel 5: Sensitivity model, model 3 plus further adjusted for WC. *P < 0.05. Assessed using multivariable weighted generalized linear regression.




Figure 3. ATC/WC and hypertension, diabetes, and resting tachycardia. The association was analyzed using a restricted cubic spline model, adjusted for age, sex, race, marital status, education, family income-poverty ratio, BMI, smoking, drinking, creatinine, uACR, hyperlipidemia, and history of underlying diseases. (A) Association between ATC/WC and hypertension. (B) Association between ATC/WC and diabetes. (C) shows the association between ATC/WC and resting tachycardia.

paradoxical associations before adiposity adjustment.

The protective associations of ATC/WC with mortality and CVRFs remained consistent across all pre-specified subgroups (stratified by sex, age, hypertension, diabetes, smoking status, and history of underlying diseases; [Supplementary Figures 7-10](#)), with generally more pronounced effects in males and older adults. In contrast, the association of ATC with outcomes was modified by certain health conditions, further underscoring its instability without considering central adiposity.

The robustness of the findings was further corroborated using continuous measures of cardiovascular risk. Furthermore, in models with full adjustment, ATC/WC showed significant inverse correlations with systolic and diastolic BP, resting heart rate, and fasting blood glucose, and these associations persisted after additional adjustment for BMI [[Supplementary Table 2](#)]. Replicating the pattern seen with dichotomous outcomes, ATC was positively associated with these continuous measures in models unadjusted for BMI, but these associations reversed direction after BMI adjustment.

Finally, deconstructing the composite metrics confirmed the generalizability of the central finding. Both the arm-to-waist (AC/WC) and thigh-to-waist (TC/WC) ratios were significantly inversely associated with all mortality and CVRF outcomes [[Supplementary Tables 3-7](#)]. Similarly, the individual circumferences (AC and TC) alone were inversely associated with mortality [[Supplementary Tables 8 and 9](#)]. Most critically, for CVRFs, the isolated arm (AC) and thigh (TC) circumferences recapitulated the identical paradoxical pattern observed for ATC: they were positively associated with hypertension, diabetes and resting tachycardia before adiposity adjustment, but these associations were attenuated, nullified, or reversed after controlling for BMI or WC [[Supplementary Tables 10-12](#)]. This confirms that the confounding effect of overall adiposity is a universal property of limb circumference measures, which is effectively resolved by forming a ratio with WC.

Collectively, these comprehensive sensitivity analyses solidify the premise that ATC/WC is a robust, adiposity-independent indicator of metabolic health, thereby resolving the confounding that inherently plagues the interpretation of limb circumferences alone.

DISCUSSION

This study demonstrates that the ATC/WC ratio exhibits a significant linear association with both mortality risk and cardiovascular risk. A graded increase in the ATC/WC value corresponds to a progressive decline in the risk of all-cause and cardiovascular mortality. A similarly stepwise reduction is observed in the likelihood

of developing multiple CVRFs. This finding reconciles a persistent paradox in the assessment of limb circumference for cardiovascular health: although greater limb circumference (reflected in a higher ATC/WC) is linked to improved survival, it has occasionally been correlated with an elevated burden of CVRFs. The study also reveals that the association between the absolute limb circumference (ATC) and mortality is nonlinear, with a protective intermediate range; both excessively low and excessively high ATC values are linked to an elevated risk of death.

Regarding CVRFs, ATC shows an increasing risk association before adjustment for adiposity, which reverses to a decreasing risk pattern after such adjustment. Furthermore, we confirmed the robustness of these associations using the arm-to-waist (AC/WC) and thigh-to-waist (TC/WC) ratios. By resolving this contradiction and elucidating the true effect of limb circumference, this approach substantially improves cardiovascular risk assessment based on body size and circumference in community healthcare settings.

Our findings consolidate and extend the existing literature. We corroborate numerous studies indicating that larger limb circumferences are associated with reduced mortality (arm^[25-30] and thigh^[31,32]). Moreover, we successfully replicate and provide a mechanistic explanation for the conflicting reports regarding limb circumference and CVRFs^[12-14,33,34]. The apparent positive association between ATC and CVRFs in unadjusted models was largely mediated by its strong correlation with general obesity. After rigorously adjusting for BMI or WC, the true protective effect of ATC on CVRFs was unmasked. This occurs because limb circumference carries dual biological signals: it reflects both beneficial lean mass and the peripheral fat deposition associated with adverse health. The protective signal for mortality is dominant, while its benefit for CVRFs is only unveiled after accounting for confounding adiposity.

This fundamental insight led us to propose ATC/WC as a novel, integrated metric. By normalizing limb size for overall body size, this index simultaneously incorporates information on central adiposity (via WC) and peripheral tissue mass (via ATC), effectively eliminating the confounding influence of adiposity. Across various models, a graded decrease in ATC/WC is consistently linked to a marked decline in mortality from all causes and cardiovascular disease. Conversely, an increase in ATC initially lowers mortality risk but shows a risk rebound starting from the highest quartile (Q4), which clearly demonstrates that it is not an ideal measure for assessing mortality risk.

The ATC/WC ratio requires no complex measurements and does not necessitate separate consideration of adiposity phenotypes. Its stable and consistent inverse association with all endpoints demonstrates its immediate potential for translation into primary care practice. First, it could be seamlessly integrated into routine health check-ups. During standard physical examinations, healthcare providers already measure WC; adding quick, standardized measurements of mid-arm and mid-thigh circumference would incur minimal additional time or cost. Second, this ratio complements existing metrics. While BMI and WC are unable to assess peripheral musculoskeletal mass, ATC/WC quantifies the balance between potentially harmful visceral fat and protective peripheral tissue. Specifically, ATC/WC can identify high-risk normal-weight phenotypes; individuals with a normal BMI but a low ATC/WC might be missed by BMI assessment alone. Finally, this metric is easily understandable for patients, serving as a tangible tool for health education. Explaining that “a healthier body shape involves not just a smaller waist but also maintaining adequate muscle and limb tissue mass” can motivate targeted lifestyle changes focused on nutrition and resistance training to improve body composition. Therefore, the ATC/WC ratio is not merely a research finding but a practical tool that can enhance risk stratification, guide patient communication, and inform personalized prevention strategies in everyday clinical practice.

For health risk assessment using ATC/WC, this study proposes two potential clinical thresholds: $ATC/WC < 0.835$ suggests elevated mortality risk, and $ATC/WC < 0.89$ indicates increased CVRF risk. Applying these thresholds suggests that approximately 25% of the U.S. adult population may face higher mortality risk, and nearly 50% have an elevated risk for CVRFs. These findings could inform the development of future public health guidelines.

Our findings are supported by biological plausibility. A high ATC/WC ratio intuitively represents a phenotype of ample peripheral tissue relative to central fat, a balance supported by the functional heterogeneity of adipose tissue and the metabolic benefits of muscle. Visceral fat, proxied by WC, is a well-established driver of insulin resistance and inflammation, promoting CVRFs^[35,36]. In contrast, limb tissue predominantly plays a protective role: muscle mass enhances metabolic health^[37-39], and limb subcutaneous fat may act as a metabolic sink^[38]. Furthermore, adequate limb circumference supports cardiorespiratory function and physical capacity^[40-42].

Several limitations should be noted. First, the observational nature of the study limits causal conclusions. Second, the applicability of the proposed thresholds beyond the U.S. population needs confirmation. Additionally, the potential for reverse causality must be carefully considered when interpreting the results. It is plausible that pre-existing cardiometabolic diseases (e.g., heart failure, advanced diabetes, cancer) could lead to cachexia, sarcopenia, or generalized muscle wasting, thereby reducing limb circumference, which might be a primary driver of the observed associations. We have taken several steps to mitigate this concern and maintain that it does not invalidate our main conclusions. First, in the mortality analysis, exposure (limb circumference) was assessed at baseline, and the outcome (death) occurred during follow-up, establishing a temporal sequence. Second, in the primary analysis of CVRFs, we statistically adjusted for a composite history of baseline health status (cardiovascular, renal, and metabolic health) and diseases (including cancer, respiratory diseases, coronary heart disease, heart failure, and stroke) across all models where possible. Third, the persistent strong, linear inverse dose-response relationship of ATC/WC across its full range, rather than a threshold effect confined to extreme values, argues against the associations being driven solely by a small subset of severely ill individuals. Most importantly, the differential findings for ATC and ATC/WC provide internal evidence against reverse causality being the sole explanation. If disease-induced muscle loss were the primary mechanism, both low ATC and low ATC/WC would be expected to correlate with poorer outcomes. However, unadjusted ATC was paradoxically positively associated with higher risks of CVRFs in our data—a pattern that reversed after adjusting for adiposity. This pattern is inconsistent with a simplistic "disease causes low limb circumference" model and instead underscores adiposity as the key confounding factor. Finally, despite adjusting for major confounders, the potential for residual confounding persists. Future studies are needed to validate the independent and joint effects of limb circumference and adiposity using different approaches, thereby addressing gaps in anthropometric knowledge.

In conclusion, we provide a practical solution to the paradox of limb circumference. The ATC/WC ratio effectively integrates and reconciles conflicting signals from body composition into a single, robust, and clinically actionable metric. This simple, low-cost tool holds considerable promise for improving cardiovascular risk assessment and advancing personalized prevention strategies.

DECLARATIONS

Acknowledgments

The authors thank all the NHANES participants and staff members for their contributions to data collection and for making the data publicly available.

Authors' contributions

Conceptualized the study, curated the data, performed formal analysis, developed the methodology, visualized the data, and wrote the original draft: Zuo S

Curated the data, validated the findings, visualized the data, and contributed to the review and editing of the

manuscript: Guo T, Ren H

Validated the data, validated the findings, and contributed to the review and editing of the manuscript:

Cao H

Curated the data, conducted investigations, and administered the project: Yang Y, Wang R, Liu C, Zhuo Y, Xia T, Yuan X, Chang M, Hu G, Sun Y, Zhang X, Du M, Jia H, Man Z, Zhang T

Developed the methodology, supervised the research, and contributed to the review and editing of the manuscript: Mu J

Funded the acquisition, developed the methodology, supervised the research, and contributed to the review and editing of the manuscript: Zuo M

All authors have read and approved the final manuscript.

Availability of data and materials

The datasets generated and analyzed during the current study are available in the NHANES repository (<https://www.cdc.gov/nchs/nhanes/index.htm>). All data can be requested from the corresponding author.

AI and AI-assisted tools statement

Not applicable.

Financial support and sponsorship

This work was supported by the Science and Technology Boosting Program Fund of Yan'an University Xianyang Hospital.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki. The National Center for Health Statistics (NCHS) Ethics Review Board (ERB) ensures that research involving human participants protects the rights and welfare of study participants and conforms to U.S. federal regulations. The NCHS ERB and the formal review bodies that preceded it have approved each NHANES study protocol since the survey began running continuously in 1999. All participants provided written informed consent. The use of publicly available de-identified data from the NHANES was determined to be exempt from review by the Ethics Committee of Yan'an University Xianyang Hospital.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2026.

Supplementary Materials

[Supplementary Materials](#)

REFERENCES

1. Brauer M, Roth GA, Aravkin AY, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2024;403:2162-203. DOI
2. Jacobs DR, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med*. 2022;386:1877-88. DOI
3. Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association's PREVENT equations. *Circulation*. 2024;149:430-49. DOI
4. Diogo R, Esteve-Altava B, Smith C, Boughner JC, Rasskin-Gutman D. Anatomical network comparison of human upper and lower, newborn and adult, and normal and abnormal limbs, with notes on development, pathology and limb serial homology vs. homoplasy. *PLoS ONE*. 2015;10:e0140030. DOI PubMed PMC

5. Dunstan DW, Daly RM, Owen N, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. *Diabetes Care*. 2002;25:1729-36. DOI
6. Cheng YJ, Gregg EW, De Rekeneire N, et al. Muscle-strengthening activity and its association with insulin sensitivity. *Diabetes Care*. 2007;30:2264-70. DOI
7. Jayedi A, Soltani S, Zargar MS, Khan TA, Shab-Bidar S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. *BMJ*. 2020;370:m3324. DOI
8. Stankute I, Dulskiene V, Kuciene R. Associations between neck circumference, mid-upper arm circumference, wrist circumference, and high blood pressure among lithuanian children and adolescents: a cross-sectional study. *Nutrients*. 2024;16:677. DOI PubMed PMC
9. Liao P, Lin Y, Ting M, et al. Adverse body measurements are superior to sarcopenia-associated measurements in predicting chronic diseases. *Sci Rep*. 2021;11:7749. DOI PubMed PMC
10. Shi R, Gao K, Gao Y, et al. Mid-arm muscle circumference and triceps skinfold thickness associated with cardiometabolic disease in Chinese residents: a prospective cohort study. *Nutr Metab Cardiovasc Dis*. 2024;34:45-54. DOI
11. Liu Y, Sun G, Li Y. A prospective cohort study on the association of lean body mass estimated by mid-upper arm muscle circumference with hypertension risk in Chinese residents. *J Clin Hypertens*. 2022;24:329-38. DOI
12. Jung KJ, Kimm H, Yun JE, Jee SH. Thigh circumference and diabetes: obesity as a potential effect modifier. *J Epidemiol*. 2013;23:329-36. DOI PubMed PMC
13. Liu J, Jin X, Feng Z, Huang J. Using anthropometric parameters to predict insulin resistance among patients without diabetes mellitus. *Sci Rep*. 2024;14:21407. DOI PubMed PMC
14. Zheng Y, Zhang J, Ren Z, et al. Prognostic value of arm circumference for cardiac damage and major adverse cardiovascular events: a friend or a foe? A 2-year follow-up in the northern Shanghai study. *Front Cardiovasc Med*. 2022;9:816011. DOI PubMed PMC
15. Hendrixson DT, Stephenson KB. To survive, yet not thrive: long-term outcomes of childhood survivors of severe acute malnutrition. *Am J Clin Nutr*. 2023;118:839-40. DOI
16. Thompson DS, Bourdon C, Massara P, et al. Childhood severe acute malnutrition is associated with metabolic changes in adulthood. *JCI Insight*. 2020;5:e141316. DOI PubMed PMC
17. Filippin LI, Teixeira VNDO, Da Silva MPM, Miraglia F, Da Silva FS. Sarcopenia: a predictor of mortality and the need for early diagnosis and intervention. *Aging Clin Exp Res*. 2014;27:249-54. DOI PubMed
18. Alberti K, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;120:1640-5. DOI
19. Xiao X, Yu X, Zhu H, et al. Arm circumference, arm-to-waist ratio in relation to cardiovascular and all-cause mortality among patients with diabetes mellitus. *Nutrients*. 2023;15:961. DOI PubMed PMC
20. Kwon HR, Han KA, Ahn HJ, Lee JH, Park GS, Min KW. The correlations between extremity circumferences with total and regional amounts of skeletal muscle and muscle strength in obese women with type 2 diabetes. *Diabetes Metab J*. 2011;35:374. DOI PubMed PMC
21. CDC. NHANES survey methods and analytic guidelines. Available from: <https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx> [Last accessed on 15 May 2026].
22. CDC. 2019 public-use linked mortality files. Available from: <https://www.cdc.gov/nchs/data/datalinkage/public-use-linked-mortality-file-description.pdf> [Last accessed on 15 May 2026].
23. CDC. NHANES August 2021-August 2023 Laboratory Methods. Available from: <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/abmethods.aspx?Cycle=2021-2023> [Last accessed on 11 May 2026].
24. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia - The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J*. 2020;41:655-720. DOI
25. Hou X, Hu J, Wang E, et al. The L-shaped association of mid-upper arm circumference with all-cause and cause-specific mortality in US adults: a population-based prospective cohort study. *BMC Public Health*. 2023;23:2297. DOI PubMed PMC
26. Chen Y, Ge W, Parvez F, et al. A prospective study of arm circumference and risk of death in Bangladesh. *Int J Epidemiol*. 2014;43:1187-96. DOI PubMed PMC
27. Shi X, Chai L, Zhang D, Fan J. Association between complementary anthropometric measures and all-cause mortality risk in adults: NHANES 2011-2016. *Eur J Clin Nutr*. 2024;79:71-8. DOI PubMed
28. Li W, Yin H, Chen Y, et al. Associations between adult triceps skinfold thickness and all-cause, cardiovascular and cerebrovascular mortality in NHANES 1999-2010: a retrospective national study. *Front Cardiovasc Med*. 2022;9:858994. DOI PubMed PMC

29. Wu L, Lin Y, Kao T, et al. Mid-arm circumference and all-cause, cardiovascular, and cancer mortality among obese and non-obese US adults: the national health and nutrition examination survey III. *Sci Rep*. 2017;7:2302. DOI PubMed PMC
30. Liu J, Jin X, Feng Z, Huang J. The association of central and extremity circumference with all-cause mortality and cardiovascular mortality: a cohort study. *Front Cardiovasc Med*. 2023;10:1251619. DOI PubMed PMC
31. Heitmann BL, Frederiksen P. Thigh circumference and risk of heart disease and premature death: prospective cohort study. *BMJ*. 2009;339:b3292. DOI PubMed PMC
32. Chen C, Liu L, Huang J, et al. Thigh circumference and risk of all-cause, cardiovascular and cerebrovascular mortality: a cohort study. *Risk Manag Healthc Policy*. 2020;13:1977-87. DOI
33. Park JS, Cho MH, Ahn CW, Kim KR, Huh KB. The association of insulin resistance and carotid atherosclerosis with thigh and calf circumference in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2012;11:62. DOI PubMed PMC
34. Li F, Chen L. The Association between trajectories of anthropometric variables and risk of diabetes among prediabetic Chinese. *Nutrients*. 2021;13:4356. DOI PubMed PMC
35. Kartheuser AH, Leonard DF, Penninckx F, et al. Waist circumference and waist/hip ratio are better predictive risk factors for mortality and morbidity after colorectal surgery than body mass index and body surface area. *Ann Surg*. 2013;258:722-30. DOI
36. Lu Y, Liu S, Qiao Y, Li G, Wu Y, Ke C. Waist-to-height ratio, waist circumference, body mass index, waist divided by height 0.5 and the risk of cardiometabolic multimorbidity: a national longitudinal cohort study. *Nutr Metab Cardiovasc Dis*. 2021;31:2644-51. DOI
37. Snijder MB, Visser M, Dekker JM, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. *Diabetologia*. 2005;48:301-8. DOI
38. Snijder MB, Dekker JM, Visser M, et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels. *Diabetes Care*. 2004;27:372-7. DOI
39. Bianchi L, Ferrucci L, Cherubini A, et al. The predictive value of the EWGSOP definition of sarcopenia: results from the in CHIANTI study. *GERONA*. 2016;71:259-64. DOI PubMed PMC
40. Hu F, Liu H, Liu X, et al. Mid-upper arm circumference as an alternative screening instrument to appendicular skeletal muscle mass index for diagnosing sarcopenia. *Clin Interv Aging*. 2021;16:1095-104. DOI
41. Kawakami R, Miyachi M, Sawada SS, et al. Cut-offs for calf circumference as a screening tool for low muscle mass: WASEDA'S Health Study. *Geriatr Gerontol Int*. 2020;20:943-50. DOI PubMed PMC
42. Zuo S, Liu C, Wang R, et al. Lifestyle factors as mediators in the relationship between depression, obesity, and blood pressure in the post-pandemic era. *Metab Target Organ Damag*. 2025;5:39. DOI

Disclaimer/Publisher's Note: All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s) and do not necessarily reflect those of OAE and/or the editor(s). OAE and/or the editor(s) disclaim any responsibility for harm to persons or property resulting from the use of any ideas, methods, instructions, or products mentioned in the content.



© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.